Supernus announces expiration of HSR waiting period for Sage Therapeutics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 28 2025
0mins
Acquisition Announcement: Supernus Pharmaceuticals has completed the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act for its acquisition of Sage Therapeutics, which was initiated with a merger agreement on June 13, 2025.
Offer Details: The Offer to Purchase will expire at 11:59 p.m. Eastern Time on July 30, 2025, unless extended or terminated, and is subject to remaining conditions outlined in the related documents.
Analyst Views on SUPN
Wall Street analysts forecast SUPN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SUPN is 60.50 USD with a low forecast of 50.00 USD and a high forecast of 65.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 50.260
Low
50.00
Averages
60.50
High
65.00
Current: 50.260
Low
50.00
Averages
60.50
High
65.00
About SUPN
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company’s diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. It is also developing a range of product candidates for CNS disorders. Its commercial products that it markets include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC and ONAPGO. Its ONAPGO injection is a subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced PD. It also offers ZURZUVAE (zuranolone) capsules CIV, which is a U.S. FDA-approved oral medicine indicated for the treatment of adults with postpartum depression.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
